Elecster (ELEAV) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
6 Jun, 2025Executive summary
Full-year revenue declined 0.6% to €33.9 million compared to 2023, with operating profit at €1.6 million, down from €2.0 million.
Q4 saw a 4.5% revenue decrease year-over-year to €8.0 million and an operating loss of €0.5 million.
Net profit for the year was €0.26 million, a turnaround from a €1.1 million loss in 2023; EPS improved to €0.07 from -€0.30.
A one-time €1 million write-down related to suspected embezzlement in China subsidiaries impacted Q4 and full-year results.
No dividend proposed for 2024, compared to €0.05 per share in 2023.
Financial highlights
Operating margin for the year was 4.7%, down from 5.9% in 2023.
Pre-tax profit reached €0.9 million, up from break-even last year.
Equity per share was €6.06, down from €6.37; equity ratio improved to 56.1% from 50.2%.
Net gearing remained stable at 31.9%.
Cash flow from operations was €1.0 million, down from €2.5 million in 2023; year-end cash was €5.5 million.
Outlook and guidance
Order backlog increased to €8.7 million from €7.4 million, supporting a positive outlook for 2025.
Revenue and EPS are expected to grow in 2025, with strong demand for dairy machinery and anticipated recovery in packaging materials in H2.
Latest events from Elecster
- Revenue up in Q4, full-year profit down; 2026 outlook positive with improved order book.ELEAV
Q4 20255 Mar 2026 - Revenue and earnings fell amid weak demand; cost-cutting and restructuring are underway.ELEAV
Q3 20257 Nov 2025 - Profitability improved sharply in 2020, with stable revenue and a positive outlook despite ongoing risks.ELEAV
Q2 202515 Aug 2025 - Net profit and EPS rose for the nine months, but Q3 performance weakened.ELEAV
Q3 202413 Jun 2025 - Strong H1 growth and improved profitability, with stable outlook despite geopolitical risks.ELEAV
Q2 202413 Jun 2025 - Revenue and profit fell in Q1, but full-year improvement is expected despite ongoing risks.ELEAV
Q1 20256 Jun 2025